Description of possible side effects of baricitinib/alenomin tablets

Baricitinib (Baricitinib) is an oral selective JAK1/JAK2 inhibitor. It mainly inhibits the activity of Janus kinase in the inflammatory signaling pathway and reduces the release of a variety of pro-inflammatory cytokines, thereby exerting anti-inflammatory and immunoregulatory effects. The drug has been widely used in autoimmune diseases such as rheumatoid arthritis and alopecia areata. With the expansion of the user population, its safety and possible side effects have gradually become the focus of both patients and doctors.

From the overall tolerability point of view, baricitinib is relatively stable in most patients, but because it directly acts on the immune signaling pathway, it may still cause a series of adverse reactions related to immunosuppression. Overseas research and real-world drug use experience suggest that the risk of infection is one of the issues that require vigilance during the use of baricitinib, especially the incidence of opportunistic infections such as upper respiratory tract infection and herpes zoster, which is of greater concern. This type of infection is often related to a decline in the body's immune monitoring ability. Therefore, it is particularly important to evaluate the infection history before medication and pay attention to abnormal fever or skin changes during medication.

In terms of hematology, some patients may experience changes in the levels of white blood cells, lymphocytes or neutrophils during treatment, which is closely related to the involvement of the JAK pathway in the regulation of hematopoiesis. Although most changes are mild to moderate and reversible, regular blood routine monitoring is still required to reduce potential risks during long-term medication or when combined with other immunosuppressive treatments. At the same time, mild elevation of liver function indicators has also been reported in some people, usually manifested as fluctuations in transaminase. In most cases, it does not affect the continued treatment, but it is still recommended to continue observation during follow-up.

In addition, baricitinib may also have certain effects on metabolism-related indicators. Overseas data show that changes in blood lipid levels can be observed in some patients after taking the drug. This phenomenon is believed to be related to the adjustment of the body's metabolic state after inflammation is suppressed, rather than a simple drug toxicity reaction.

Reference materials:https://go.drugbank.com/drugs/DB11817